Hunterdon Hematology Oncology

Flemington, New Jersey 08822-4603

2 studies enrolling now · 11 studies all time

What they study most

BRAF Gene Mutation, Bladder Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chemotherapy-induced Peripheral Neuropathy, Cholangiocarcinoma, Colorectal Cancer, ERK Mutation, Early Breast Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Studies at this site

• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — Recruiting now
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia — Running, not enrolling
• A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer — Completed
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies — Available (expanded access)
• A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment — Completed
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants — Stopped early
• Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) — Stopped early
• TR(ACE) Assay Clinical Specimen Study — Status unconfirmed